Clinical trials: Patients with Multiple Sclerosis
Relapsing Remitting Multiple Sclerosis
Long-term Effect of Fingolimod on Circulating Immunocompetent Mononuclear Cells in Patients With Multiple Sclerosis
The purpose of this study is to explore immunomodulatory and immunosuppressive mechanisms of action of fingolimod in patients with Relapsing remitting multiple Sclerosis to collect data on biomarkers after initiation of…
- Trial name
- BiobankII (NCT01755871)
- Testing
- Fingolimod
- Where
- Germany
- Volunteers
- 8 people
- Sponsor
- Heinrich-Heine University, Duesseldorf
Multiple Sclerosis (MS), Neuromyelitis Optica Spectrum Disorder (NMOSD)
Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.
This study is an open-label, exploratory, prospective clinical trial with dose escalation(according to "3+3" design), to evaluate the safety and tolerability of QH103(Universal CD19 CAR-γδT Cell Injection)in the treatment of…
- Conditions
- Multiple Sclerosis (MS), Neuromyelitis Optica Spectrum Disorder (NMOSD), Autoimmune Encephalitis (AE), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- Trial name
- NCT07526493
- Testing
- Universal CD19 CAR-γδT Cell Injection, Cyclophosphamide, Fludarabine
- Where
- China
- Volunteers
- 6 people
- Sponsor
- Tongji Hospital
Multiple Sclerosis
Effect of Artificial Intelligence Based Cognitive Training on Sleep Disorders and Quality of Life in Patients With Multiple Sclerosis
this study will be conducted to investigate the effect of artificial intelligence (AI) based cognitive training on sleep disorders and quality of life in patients with multiple sclerosis.
- Trial name
- AI (NCT07762326)
- Testing
- cognitive Therapy by artificial intillegence, designed physical-therapy program
- Volunteers
- 40 people
- Sponsor
- Cairo University
Multiple Sclerosis (MS)
Safety and Effectiveness of Nabiximols Oromucosal Spray as Add-on Therapy in Participants With Spasticity Due to Multiple Sclerosis
This trial is being conducted to demonstrate the efficacy of nabiximols, compared with placebo, when added to standard of care, in the treatment of muscle spasms associated with multiple sclerosis (MS).
- Trial name
- RELEASE MSS3 (NCT04203498)
- Testing
- Nabiximols
- Where
- 37 sites in United States, Czechia and 3 more
- Volunteers
- 139 people
- Sponsor
- Jazz Pharmaceuticals
Multiple Sclerosis
Cognitive Stimulation in Patients With Sclerosis Multiple
The primary objective of the study is to determine if the training for 6 months with a specific set of games ( previously selected according to the cognitive domain stimulate : attention, memory , executive functions and…
- Trial name
- JuguEMos (NCT06714487)
- Testing
- cognitive stimulation through games
- Volunteers
- 80 people
- Sponsor
- Institut Investigacio Sanitaria Pere Virgili
Relapsing Remitting Multiple Sclerosis, Sleep Initiation and Maintenance Disorders
Eszopiclone for Improving Sleep in Multiple Sclerosis (MS)
The purpose of this study is to determine if people with multiple sclerosis (MS) and fatigue have disrupted sleep, as was suggested in previous studies, and whether treating the disruptions of sleep improves the fatigue.
- Conditions
- Relapsing Remitting Multiple Sclerosis, Sleep Initiation and Maintenance Disorders, Fatigue
- Trial name
- NCT00594087
- Testing
- eszopiclone
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Vermont
Multiple Sclerosis, Lower Urinary Track Symptoms
Silodosin for Urinary Symptoms in Female Patients With Multiple Sclerosis
The goal of this clinical trial is to learn if silodosin works to treat lower urinary tract symptoms (LUTS) in female patients with multiple sclerosis (MS). It will also learn about the effect of the drug on voiding parameters.
- Trial name
- NCT07614321
- Testing
- Silodosin 8 mg
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Atlantic Health System
Multiple Sclerosis
Stem Cell Therapy for Patients With Multiple Sclerosis Failing Alternate Approved Therapy- A Randomized Study
Multiple sclerosis (MS) is at onset an immune-mediated demyelinating disease. In most cases, it starts as a relapsing-remitting disease with distinct attacks and no symptoms between flares.
- Trial name
- NCT00273364
- Testing
- Hematopoietic Stem Cell Therapy, Standard treatment with a conventional drug
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- Northwestern University
Multiple Sclerosis, Radiologically Isolated Syndrome
Prognostic Value of Three New Biomarkers of Multiple Sclerosis in Patients With Radiologically Isolated Syndrome
To look at the prognostic value of new biomarkers in CSF and serum for characterisation of multiple sclerosis
- Trial name
- T-RIS (NCT03357887)
- Testing
- Analysis of cerebrospinal fluid and serum
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Multiple Sclerosis
Effect of Adding Modified Ketogenic Diet to Exercise Program in Treating Obese Patient With Multiple Sclerosis: A Randomized Controlled Trial
this study will be conducted to investigate the effect of adding Modified Ketogenic diet to exercise program in treating obese patient with multiple sclerosis.
- Trial name
- MS (NCT06454162)
- Testing
- Modified Ketogenic Diet, exercise program
- Volunteers
- 64 people
- Sponsor
- Cairo University
Multiple Sclerosis
A Study to Evaluate the Real-world Experience and Satisfaction Associated With Ofatumumab
The aim of this study was to assess physician and patient satisfaction with ofatumumab using data collected from physicians and their multiple sclerosis (MS) patients in real-world clinical practice across the United Kingdom…
- Trial name
- NCT07504783
- Where
- Switzerland
- Volunteers
- 261 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis, Relapsing Remitting
Sexual Dysfunction, Disability and Quality of Life in Patients With Multiple Sclerosis (MS)
This is an observational, prospective, non-interventional, non-controlled study planned to be conducted in subjects with Relapsing-Remitting Multiple Sclerosis (RRMS).
- Trial name
- NCT01080053
- Where
- Argentina
- Volunteers
- 306 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Multiple Sclerosis
Diclofenac Sodium Topical Gel to Reduce Injection Site Discomfort in Patients Taking Glatiramer Acetate
The purpose of this study is to assess the effect of Diclofenac Sodium Topical Gel (DSTG) on injection site reaction following self-administer glatiramer acetate in people with Multiple Sclerosis.
- Trial name
- NCT01454791
- Testing
- diclofenac sodium topical gel
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Brown, Theodore R., M.D., MPH
Neurological Diseases or Conditions, Dementia of Alzheimer Type
An Observational Study of Patients Living With Chronic Neurological Diseases
TARGET-NEURO is an observational research study to conduct a comprehensive review of outcomes for patients living with chronic neurological diseases: Alzheimer's disease and related dementia (ADRD), mild cognitive impairment…
- Conditions
- Neurological Diseases or Conditions, Dementia of Alzheimer Type, Alzheimer Disease, Mild Cognitive Impairment
- Trial name
- NCT05796037
- Volunteers
- 1,500,000 people
- Sponsor
- Target PharmaSolutions, Inc.
Multiple Sclerosis, Relapsing-Remitting, Vaccine Response Impaired
Immune Response to Seasonal Influenza Vaccination in Multiple Sclerosis Patients Receiving Cladribine
The primary objective of this study is to characterize the antibody response to seasonal influenza vaccine, in patients with active RRMS, treated with cladribine, compared to control individuals with basic immunomodulatory…
- Trial name
- CIRMS (NCT05019248)
- Testing
- Most recent vaccine to seasonal influenza
- Where
- Germany
- Volunteers
- 260 people
- Sponsor
- Heinrich-Heine University, Duesseldorf
Multiple Sclerosis, Disease Management
Feasibility Study of a Relapse Investigation Questionnaire Administered by an MS Care Coordinator Nurse in Patients With Multiple Sclerosis
This study aims to evaluate a questionnaire used by a specialized nurse to help manage relapses in people with multiple sclerosis (MS).
- Conditions
- Multiple Sclerosis, Disease Management, Feasibility Studies
- Trial name
- NCT06994026
- Where
- France
- Volunteers
- 10 people
- Sponsor
- Centre Hospitalier de Gonesse
Tuberous Sclerosis, Lymphangioleiomyomatosis
Rapamycin Therapy for Patients With Tuberous Sclerosis Complex and Sporadic LAM
The purpose of this study was to determine if rapamycin reduced angiomyolipomata volume in patients with tuberous sclerosis complex or lam.
- Trial name
- NCT00457808
- Testing
- Rapamycin, sirolimus
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Multiple Sclerosis (MS), Neurogenic Bladder Disorder
Essential Oils for Urinary Symptoms in Multiple Sclerosis Patients
The goal of this clinical trial is to learn if essential oil aromatherapy works to improve urinary symptoms in adults with multiple sclerosis. It will also learn about the safety of essential oil use in this population.
- Conditions
- Multiple Sclerosis (MS), Neurogenic Bladder Disorder, Urinary Incontinence (UI), Urinary Urgency
- Trial name
- AROMA-MS (NCT07599189)
- Testing
- Essential Oil Blend (Lavender, Rosemary), Neutral Carrier Oil (Apricot Kernel Oil)
- Where
- 2 sites in Algeria
- Volunteers
- 60 people
- Sponsor
- University of Oran 1
Multiple Sclerosis
Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase
This study assessed the safety, tolerability, and efficacy of 2 doses of oral fingolimod versus interferon β-1a to reduce the frequency of relapses in patients with relapsing-remitting multiple sclerosis.
- Trial name
- TRANSFORMS (NCT00340834)
- Testing
- Fingolimod 1.25 mg, Fingolimod 0.5 mg, Interferon β-1a 30 µg
- Where
- 170 sites in United States, Argentina and 16 more
- Volunteers
- 1,292 people
- Sponsor
- Novartis
Multiple Sclerosis
A Longitudinal Study of Effect of Copaxone in RRMS Over 24 Months
To explore whether treatment with glatiramer acetate (GA) may decrease iron deposition in subcortical deep GM, as detected by SWI-filtered phase imaging, in patients with RRMS over 24 months and compared to a reference population…
- Trial name
- GASWI (NCT01695434)
- Testing
- MRI
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University at Buffalo
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.